In the third quarter, Banyan Capital Management initiated a stake in Johnson & Johnson by acquiring 3,853 shares with a fair-value of $714,000, representing 0.3% of its portfolio and ranking J&J as its 22nd largest holding. This move follows Norges Bank’s entrance in the second quarter with a $4.88 billion purchase, Laurel Wealth Advisors’ 15,040.6% increase to 7.42 million shares valued at $1.13 billion, Vanguard’s 1.3% lift to 237.05 million shares worth $36.21 billion, and Geode Capital’s 2.1% rise to 60.61 million shares worth $9.23 billion. Legal & General Group also expanded by 6.2% to 18.92 million shares valued at $2.89 billion. Institutional holdings now comprise 69.55% of the company’s shares outstanding.

The European Medicines Agency’s positive opinion for AKEEGA in BRCA1/2-mutant metastatic hormone-sensitive prostate cancer underscores new oncology revenue potential, enhancing J&J’s pharmaceutical growth trajectory. Reflecting that progress, Daiwa Capital Markets raised its target to $237 with an Outperform rating, Morgan Stanley upgraded based on an improved growth outlook, and Scotiabank lifted its target to $265 while reiterating an Outperform stance. Consensus among sell-side analysts remains cautiously optimistic, with an average moderate-buy recommendation and a mean objective near $233.

In its Q4 report, Johnson & Johnson delivered $24.56 billion in revenue—up 9.1% year-over-year—and matched consensus at $2.46 in earnings per share. Net margin stood at 28.46%, return on equity at 33.34%, and the company reaffirmed fiscal 2026 earnings guidance of $11.43–$11.63 per share. On the balance sheet, debt-to-equity remains 0.50, current and quick ratios at 1.07 and 0.80 respectively. The board declared a $1.30 quarterly dividend—the 63rd consecutive annual increase—payable March 10 to shareholders of record February 24, yielding approximately 2.3% on an annualized basis.